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KESAN EKSTRAK TERPIAWAI EURYCOMA LONGIFOLIA KE ATAS 
LINTASAN METABOLIK FASA I DAN FASA II DAN FARMAKOKINETIK 
ROSIGLITAZON 
 
 
ABSTRAK 
 
 
Kepercayaan bahawa produk semula jadi adalah lebih selamat daripada ubat-
ubat sintetik telah membawa kepada pertumbuhan dramatik penggunaan persediaan 
herba. Walau bagaimanapun, persediaan herba juga mempunyai potensi untuk 
menyebabkan ketoksikan, interaksi ubat-herba dan boleh menjejaskan kesan 
terapeutik ubat. Eurycoma longifolia Jack (Tongkat Ali) telah digunakan secara 
meluas oleh penduduk tempatan sebagai aprodisiak dan mengandungi banyak 
sebatian kimia yang perlu dipantau samada wujudnya interaksi ubat-herba. Oleh itu, 
kajian mengenai kesan-kesan ekstrak E. longifolia terpiawai (TAF-273) ke atas profil 
farmakologi membabitkan metabolisme fasa I dan II, dan farmakokinetik 
rosiglitazon perlu dijalankan untuk memastikan keberkesanan dan keselamatan 
penggunaannya.  
 
Kesan in vitro ekstrak TAF-273 E. longifolia kaya quassinoid terpiawai ke 
atas metabolisme aminopirina dan rosiglitazon telah dikaji. TAF-273 meningkatkan 
metabolisme aminopirina secara signifikan (P < 0.05) khasnya dalam tikus normal 
dewasa jantan dan betina. Pada sisi lain, TAF-273 meningkatkan secara signifikan (P 
< 0.05) metabolisme rosiglitazon khasnya dalam tikus jantan tua normal dan diabetik. 
Kesan in vivo TAF-273 dalam tikus ke atas fasa I metabolisme rosiglitazon adalah 
meningkat secara signifikan (P < 0.001) untuk semua haiwan bagi semua dos (5 to 
1000 mg/kg) kecuali pada 1 mg/kg (P > 0.05). Mekanisme TAF-273 meningkatkan 
metabolisme aminopirina dalam tikus dewasa jantan mungkin diperantarakan melalui 
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perencatan tirosina kinase dan pengaktifan protein G, PKG, PKA dalam laluan cAMP, 
kalmodulin dan PKC, manakala dalam tikus dewasa betina, mungkin diperantarakan 
melalui pengaktifan protein G, PKG, PKA dalam laluan cAMP dan PKC. Kesan TAF-
273 keatas metabolisme fasa I rosiglitazon dalam tikus tua jantan diabetik mungkin 
diperantarakan melalui pengaktifan protein G, PKA dalam laluan cAMP, calmodulin 
dan PKC manakala dalam tikus tua jantan normal mungkin diperantarakan melalui 
perencatan protein fosfatase dan tirosina kinase. 
 
Dalam kajian ke atas metabolism fasa II, TAF-273 menurunkan secara 
signifikan aktiviti UGT in vitro, dengan IC50 0.74 µg/mL, manakala kesan TAF-273 
ke atas aktiviti GST hanya ditemui pada kepekatan tertinggi yang dikaji (1000 
µg/mL; P < 0.01). Dalam kajian in vivo, penurunan signifikan (P < 0.01 dan P < 
0.001) aktiviti UGT telah ditemui dalam kajian akut dan sub-akut. Kesan TAF-273 
ke atas aktiviti GST in vivo didapati berbeza, TAF-273 menurunkan secara signifikan 
(P < 0.001) aktiviti GST dalam kajian akut manakala dalam kajian sub-akut, TAF-
273 meningkatkan secara signifikan (P < 0.001) aktiviti GST 10% sampai 13%. IC50 
TAF-273 pada perencatan CYP2D6, CYP3A4 dan CYP1A2 aktiviti tidak dapat 
ditentukan, sebaliknya kajian perencatan TAF-273 dan eurikomanon ke atas aktiviti 
CYP2C9 dan CYP2C19 menunjukkan bahawa TAF-273 dan eurikomanon bukan 
perencat poten untuk CYP2C9 dan CYP2C19 dengan IC50 eurikomanon 47.33 µM 
dan 167.88 µM. Kesan TAF-273 ke atas farmakokinetik rosiglitazon telah 
diperhatikan untuk kajian kedua-dua oral dan intravena. TAF-273 meningkatkan 
secara signifikan (P < 0.05) isipadu (Vd) dan klearans (CL) rosiglitazon sebesar 
19.69 % dan 12.41 % dalam kajian oral, tetapi tidak menunjukkan perubahan 
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signifikan keatas profil farmakokinetik dan bioavailabiliti rosiglitazon dalam kajian 
intravena. 
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THE EFFECT OF STANDARDIZED EXTRACT OF EURYCOMA 
LONGIFOLIA ON PHASE I AND PHASE II METABOLIC 
PATHWAYS AND ROSIGLITAZONE PHARMACOKINETICS  
  
ABSTRACT 
 
 
The belief that natural products are safer than synthetic drugs has led to the 
dramatic growth in herbal medicine usage. However, herbal preparations have the 
potential to cause toxicity, herb-drug interactions and may affect the drug therapeutic 
effects. Eurycoma longifolia Jack (Tongkat Ali) has been widely used by the local 
population as an aphrodisiac, and contains many chemical constituents which should 
be monitored for herb-drug interactions. Therefore, study about the effects of the 
standardized extract of E. longifolia on the pharmacological profile involving 
metabolism phase I and II, and the pharmacokinetics of rosiglitazone needs to be 
conducted to ensure the efficacy and safety of use.  
 
The in vitro effect of a standardized quassinoid-rich E. longifolia extract 
(TAF-273) on aminopyrine and rosiglitazone metabolism was studied. TAF-273 
increased significantly aminopyrine metabolism (P < 0.05) especially in the adult 
normal male and female rats. On the other hand, TAF-273 increased rosiglitazone 
metabolism in vitro significantly (P < 0.05) especially in the old normal and diabetic 
male rats. The in vivo effect of TAF-273 in rats on phase I rosiglitazone metabolism 
was significant increase (P < 0.001) in all animals for all the doses (5 to 1000 mg/kg) 
except at 1 mg/kg (P > 0.05). The mechanism of TAF-273 in increasing the 
aminopyrine metabolism in adult male rat was probably mediated through the 
inhibition of tyrosine kinases and the activation of G-protein, PKG, PKA in the cAMP 
pathway, calmodulin and PKC, while in the adult female rat was probably mediated 
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through the activation of G-protein, PKG, PKA in cAMP pathway and PKC. The effect 
of TAF-273 on phase I rosiglitazone metabolism in the old diabetic male rat was 
probably mediated through the activation of G-protein, PKA in the cAMP pathway, 
calmodulin and PKC, while in the old normal male rat was probably mediated 
through the inhibition of protein phosphatase and tyrosine kinase. 
 
In phase II metabolism studies, TAF-273 decreased significantly the in vitro 
UGT activity, with IC50 of 0.74 µg/mL, while TAF-273 effect on GST activity  in 
vitro was only found at the highest concentration tested (1000 µg/mL; P < 0.01). In 
the in vivo assay, a significant decrease (P < 0.01 and P < 0.001) in the UGT activity 
was found in the acute and sub-acute studies. Effect of TAF-273 on the GST activity 
in vivo was found different: TAF-273 decreased significantly (P < 0.001) the GST 
activity in the acute study, whereas in the sub-acute study, TAF-273 increased 
significantly (P < 0.001) the GST activity from 10 to 13%. The IC50 of TAF-273 on 
the inhibition of CYP2D6, CYP3A4 and CYP1A2 activity could not be determined, 
while the inhibition studies of TAF-273 and eurycomanone on the CYP2C9 and 
CYP2C19 activities indicated that TAF-273 and eurycomanone were not potent 
inhibitors for both CYP2C9 and CYP2C19 with the eurycomanone IC50 of 47.33 µM 
and 167.88 µM. The effect of TAF-273 on the rosiglitazone pharmacokinetics has 
been observed for both oral and intravenous studies. TAF-273 increased significantly 
(P < 0.05) the volume of distribution (Vd) and clearance (CL) rosiglitazone by 19.69 
% and 12.41 % in the oral study, but did not show significant changes on the 
pharmacokinetic profile and bioavailability of rosiglitazone in the intravenous study.  
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CHAPTER ONE 
INTRODUCTION AND LITERATURE REVIEW 
 
 
1.1    INTRODUCTION 
Herbal medicines have been used for a long time (Zhang et al., 2005) and the 
market has been rapidly growth. The usage of herbal preparations is widespread 
especially in China, South and Central America, Africa, Indonesia, India and Pacific 
Islands, United States, Suriname, Ghana and Peru (Bhattaram et al., 2002, Barnes et 
al., 2008; Bussmann & Sharon, 2009; Van-Andel et al., 2012; Van-Andel & 
Carvalheiro, 2013). Demand for natural supplements including traditional medicines 
increase over the years. According to analysis of BCC Research, herbal supplements 
have grown at a Compounded Annual Growth Rate (CAGR) of 3 % and contribute 
more than $83 billion to the overall healthcare market (Valvis, 2011). In Europe, the 
total herbal products over-the-counter (OTC) in 1991 and 1992 were £1.45 billion 
and £3.31 billion, respectively (Barnes et al., 1998). The increase of herbal sales in 
the United States was approximately 25 % per year. The data showed a rise from $1 
billion in 1994 to $4 billion in 1998 (Bent & Ko, 2004). The estimation of traditional 
medicines market and other health foods in Malaysia are between US$526 to 
US$790 million (Noordin et al, 2008). Abu Kasim (2007) reported that the total 
value of herbal industry in the Malaysian market reached RM4.55 billion in 1999 and 
the market value was estimated at RM7.97 billion in 2005.  
A herb-drug interaction can be defined as pharmacologic or clinical response 
to the coadministration of a traditional drug or pharmaceutical preparation and a 
herbal product (Brazier & Levine, 2003). The use of herbal remedies that are often 
coadministered with prescribed drugs could raise the potential of herb-drug 
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interactions (Zhou et al., 2004). The belief among many users and suppliers of herbal 
drugs that these preparations are natural and safe for consumption have resulted in 
many herbal products on sale in the market (Zhang et al., 2005; Newall et al., 1996). 
However, it is possible that one substance may alter the bioavailability of another 
substance by inducing phase I or phase II hepatic metabolism that can affect the drug 
therapeutic response. There are many reports on herb-drug interactions, adverse 
effects of herbs and their abilities to influence the therapeutic effect of clinical drugs 
(Ernst, 2002; Mills et al., 2005; Low & Tan, 2007). The concurrent use of herbal 
medicines with synthetic drugs, can mimic, synergistic or contradict the effects of the 
drugs (Fugh-Berman, 2000), where the interactions may cause some serious clinical 
consequences (Izzo & Ernst, 2001; Zhou et al., 2004; Saxena et al., 2008). Effects of 
herbal preparations on metabolism and pharmacokinetic processes are shown in 
Tables 1.1 and 1.2, while, Table 1.3 shows the effects of some herbal preparations or 
compounds derived from medicinal plants on UDP-glucuronosyltransferase (UGT) 
and glutathione-S-transferase (GST) activities. Thus, studies about the effect of 
herbal medicines on pharmacological profile involving drug metabolism phase I or II, 
and the pharmacokinetics study of drugs will become the important findings for 
rational usage of herbal remedies (Zhang et al., 2005). 
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Table 1.1 Assessment of medicinal plants on drug interactions and effects 
on cytochrome (CYP) activities (Saxena et al., 2008) 
 
No Medicinal plants and 
herbal constituent 
Drug Experimental 
model 
Symptom of 
interaction 
Mechanism 
 
1 
 
St. John’s Wort 
(Hypericum 
perforatum): Hyperforin 
 
 
Cyclosporin 
 
Human 
hepatocytes 
 
Reduction of 
serum 
cyclosporin 
concentration  
 
 
Induction of 
CYP3A4 by 
hyperforin 
2 St. John’s Wort 
(Hypericum 
perforatum): Hyperforin 
 
Omeprazole Human 
clinical trial 
Decrease of 
omeprazole 
plasma 
concentration 
 
Induction of 
CYP2C19, 3A4 
by hyperforin 
3 Garlic (Allium sativum): 
Allicin 
Saquinavir Human 
clinical trial 
Decrease of 
saquinavir 
bioavailability 
Induction of 
CYP3A4 by 
allicin 
 
4 Piper nigrum: Piperin 
 
Phenytoin, 
propranolol, 
theophylline 
 
Human 
clinical trial 
Increase the  
bioavailability of 
phenytoin, 
propranolol and 
theophylline 
  
Piperine 
suppressed 
CYP2E1 
expression 
5 Gingko (Gingko biloba): 
Ginkgolic acid 
Diltiazem In vitro and 
in vivo 
analysis on 
rat hepatic 
and intestinal 
CYP 
enzymes 
 
Inhibition of 
diltiazem 
metabolism   
The leaf extract 
inhibited 
CYP3A activity 
and ginkgolic 
acids showed 
inhibition on 
CYP1A2, 
CYP2C9, 
CYP2C19 
activity 
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Table 1.2 Pharmacokinetic effect of herbal medicines on some drugs 
(Izzo & Ernst, 2001; Zhang et al., 2005; Zhou et al., 2004) 
 
No Herbal Medicines Pharmacokinetic effect 
 
1 St John’s Wort/ SJW 
(Hypericum perforatum) 
a. Decreases the plasma concentration of simvastatin 
    and the active metabolite (simvastatin acid) 
b. Decreases cyclosporine blood concentration leading 
    to organ rejection 
c. Increases the clearance of alprazolam  
d. Does not alter the pharmacokinetics of tolbutamide, 
    but increases the incidence of hypoglycemia 
 
2 Garlic (Allium sativum L.) a. Decreases the AUC of saquinavir and ritonavir, and    
  Cmax of saquinavir 
b. Changes pharmacokinetic variables of paracetamol 
c. Decreases blood concentrations of warfarin and   
    produces hypoglycaemia when taken with   
    chlorpropamide 
 
3 Echinacea (Echinacea 
purpurea root) 
a. Reduces the oral clearance of caffeine and tolbutamide 
b. Increases the systemic clearance of midazolam 
 
4 Ephedra (Ephedra sinica)    The pH dependence of renal elimination of the 
   ephedrine alkaloids which could lead to undesirable  
   side effects in  persons with high urine pH values 
 
5 Ginseng (Panax ginseng)    Lowers the blood concentrations of alcohol and  
   warfarin 
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Table 1.3 Effect of herbal medicines or compounds derived from medicinal 
plants on UDP-glucuronosyltransferase (UGT) and glutathione-S-transferase 
(GST) activities 
 
No Herbal medicines or 
compounds derived from 
medicinal plants 
 
Effect on UGT and GST activities 
 
References 
1 Carnosol (phenolic 
diterpene) 
Increased GST activity in human cells 
in rat liver 
 
Singletary, 1996 
2 Tannic acid and butein Decreased GST activity 
 
Zhang et al., 1997 
3 Flavones and flavanones Increased UGT and GST activities in 
rat liver 
 
Hodex et al., 2002 
4 Protocatechuic acid Increased UGT and GST activities in 
rat liver 
 
Krajka-Ku´zniak et 
al., 2004 
5 Orthosiphon stamineus 
leaf extracts 
Increased both UGT and GST activity in 
diabetic rat liver 
 
Han et al. 2009 
6 Flavonoids of Ginkgo 
biloba extract 
Induced the expression of UGT1A1 
and CYP1A2 in HepG2 cells 
 
Li et al., 2009 
7 Morinda citrifolia (Noni) 
juice 
Decreased the UGT activity and 
increased the GST activity in rat liver 
 
Mahfoudh et al., 
2009 
8 Mitragyna speciosa Korth 
extract 
 
Increased GST activity  in rat liver Azizi et al., 2010 
9 Andrographis paniculata 
and Orthosiphon 
stamineus extracts 
Decreased of some human UGT 
isoforms activities 
Ismail et al., 2010 
 
 
 
 
1.2    LITERATUR REVIEW 
1.2.1 Testosterone level and erectile dysfunction (ED) 
Based on one analysis that used a large member of male subjects, there was a 
relationship between testosterone level and health. The increase of testosterone levels 
in men may reduce some symptoms such as depression, obesity, high blood pressure, 
frequent colds and heart attacks (Booth et al., 1999). The relationship between 
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testosterone and obesity was on the relationship of testosterone and muscle mass. 
Testosterone was related to the development of skeletal muscle mass especially in 
protein synthesis (Freedman et al., 1991; Ozata et al., 1996; Booth et al., 1999). 
Most of medical research literatures have focused on the treatment of hypogonadism 
and at normal levels, testosterone could improve sexual function and mood 
(Davidson et al., 1979; Billington et al., 1983; Arver et al., 1996; Wang et al., 1996) 
and increase skeletal muscle mass (Brodsky et al., 1996).  
 
Many chronic diseases, such as cardiovascular diseases, hypogonadism and 
diabetes mellitus, may affect the sexual function and have been significantly related 
to sexual dysfunction (Wespes, 2002). According to previous studies, testosterone 
deficiency, previously recognized as common in men with type 2 diabetes, was also 
common in men with type 1 diabetes (Rhoden et al., 2005; Tomar et al., 2006; 
Chandel et al., 2008). Low testosterone levels may cause health problems that lead to 
erectile dysfunction (Marbeger et al., 2006). 
 
1.2.2 Erectile dysfunction therapies 
As many as 70 million men were affected by erectile dysfunction (ED) in 
Europe and North America (Wood, 2000) and around 30 million men were affected 
in the United States. With aging, the frequency of ED can increase although not 
always due to aging process. About 25% of men over 65 years of age have some 
degree of ED. According to one study on ED prevalence (The Massachusetts Male 
Aging Study), about 52 % of men suffered from ED, at 40 to 70 years (Feldman, 
1994). 
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Not only in America and Europe, ED has been known to be a common sexual 
problem amongst Asian men. In a study of men aged from 40 to 70 years in four 
Asian countries, including Malaysia and Japan, it was found that the prevalence of 
ED (from moderate to complete ED) was 22 % and 34 % (Nicolosi et al., 2003). In 
China, the prevalence of ED was 28.3 % (Bai et al., 2004), in Korea, it was 32.2 % 
(Cho et al., 2003) and in Taiwan, 17.7 % (Chen et al., 2004). Many Asian men have 
used traditional medicine for the treatment of ED problems (Fisher et al., 2005). 
Some of traditional medicines used in Asia to increases libido, vitality and sexual 
energy are shown in Table 1.4 (Low & Tan 2007). 
 
In "The Asian Men’s Attitudes towards Life Events and Sexuality (Asian 
MALES) Study", 65 % of the Malaysia's respondents preferred using traditional 
remedies because they believed that they can improve overall well being including 
blood circulation, cure ED with fewer adverse events (Low & Tan., 2007). Therefore, 
many Asians choose traditional medicine for treatment rather than Westerns 
medicine (MacKay, 2004). 
 
Table 1.4 Various traditional medicines used in Asia-Pacific (Low & Tan, 2007) 
 
Traditional medicines Country Traditional medicines Country 
 
Tongkat Ali 
Badam 
Horny goat weed 
Tiger penis 
Powered Rhino horn 
Stag penis 
Malaysia 
India 
Australia 
Asia 
Asia 
Asia 
Three penis wine 
Panax ginseng (Rhen Shen) 
Gingko + Panax ginseng 
Yin Guo + Sarsaparilla 
Panax ginseng + Epimedium 
Curculi orchlodes (Xian Mao) 
Asia 
China 
China 
China 
China 
China 
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Some natural products that were used to cure erectile-dysfunction included 
dehydroepiandrosterone, yohimbine, l-citrulline, pyrano-isoflavones, berberine, 
papaverine, prostaglandin E1 and forskolin. Some preparations contained the crude 
extracts or purified extracts and others contained a mixture of identified compounds 
derived from the natural sources, such as preparations of Tribulus terrestris, lipidic 
extract from Lepidium meyenii (maca), ginseng from Panax ginseng or P. 
quinquefolius, Eurycoma longifolia extracts,  products from Cordyceps sinensis and 
catuama herbal medicine that consists of Trichilia catigua, Paullina cupana, 
Ptychopetalum olacides and Zingiber officinalis (Drewes et al., 2003). In Malaysia, 
some of the traditional remedies include the animal parts such as deer antlers and 
tails, rhinoceros horn and tiger penis, or medicinal herbs including ginseng (Panax 
ginseng), Linzhi Jamu (Ganoderma) and Tongkat Ali (Eurycoma longifolia) (Low et 
al., 2002; 2004). 
 
 
1.2.3 Eurycoma longifolia Jack (E. longifolia) 
E. longifolia is a tall tree belonging to the Simaroubaceae family, has been 
popular in Asia and is distributed in the forests of Burma, Southern Myanmar, 
Thailand, Indochina (Cambodia, Laos and Vietnam), Sumatra, Borneo, Philippines 
and Malaysia. E. longfolia has many local names: in Brunei is known as tungat ali, 
langsia siam or pasak bumi; in Indonesia is known as beseng, bidara laut or pasak 
bumi; in Cambodia is known as antoung sar or antong sar; in Laos is known as tho 
nan; in Thailand is known as plaalai phuenk, hae phan chan or phiak; in Vietnam is 
known as Cay ba binh and in Malaysia is known as bedara putih, bedara merah or 
tongkat ali (Chan et al, 1998; Uji, 1999). The plant has a habit as spindly unbranched 
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tree or grows to a height of 10 m with a few upright branches with stems of grayish 
brown colour and each forming an umbrella-like rosette of leaves (Figure 1.1).  
 
 
Figure 1.1 Eurycoma longifolia Jack (Tongkat Ali) 
 
The E. longifolia has a classification as follows: 
Kingdom  : Plantae  
Super Division : Spermatophyta 
Division  : Magnoliophyta  
Class   : Magnoliopsida  
Subclass  : Rosidae  
Order   : Sapindales  
Family   : Simaroubaceae  
Genus   : Eurycoma  
Species       : Eurycoma longifolia Jack (Cronquist, 1981) 
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In Malaysia, Tongkat Ali has been claimed to improve the stamina of men 
during sexual activities, increase the vitality and restore erection. Therefore, it has 
been reputed as an aphrodisiac. The herb is commonly taken as a decoction of roots 
in water. Nearly 200 Tongkat Ali products are available on the domestic Malaysian 
market, in either in combination of herbs or single preparation (Cyranoski, 2005). 
 
Many publications have revealed the aphrodisiac activity of E. longifolia 
which has been used to enhance male virility during sexual activities. The effects of 
some E. longifolia root extracts (methanol, butanol, chloroform and water) to 
enhance the libido of male rats had been evaluated by Ang & Sim (1997). The rats 
were treated with E. longifolia at various doses (200, 400 and 800 mg/kg) for ten 
days, twice daily. The results showed a rise in the mounting frequency. The results 
suggesting that E. longifolia have an ability to stimulate the sexual arousal in male 
rats. Ang & Ngai (2001) examined the aphrodisiac activity of E. longifolia in 
noncopulator male rats. They used the electrical cage method. Fractions of E. 
longifolia (0.5 g/kg) decreased the hesitation time of male rats during the 
investigation period. The results support the usage of the plant as a traditional 
medicine for the aphrodisiac ability. Another experiment by Ang & Lee (2002) gave 
the evidence that the middle-aged male rats which were treated with different 
fractions of E. longifolia extract (800 mg/kg) showed the changes in sexual behavior. 
The rats exhibited an increase in the orientation activities including licking, sniffing 
and mounting towards the females. The sexual motivation activity of male mice with 
different ages after being treated with extract of E. longifolia daily for ten days (500 
mg/kg) reported by Ang et al. (2003a). A momentary increase occurred in the 
percent of mice responding after administering the extract by 50 % of the adult 
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middle-aged male mice. Later, the effect of the E. longifolia crude extract in ethanol 
on the release of testosterone had been identified. It was reported that the ethanolic 
crude extract decreased the basal release of testosterone. On the other hand, the crude 
extract increased the production of testosterone induced by the human chorionic 
gonadotropin (hcG) in rat Leydig cells (Lin et al., 2001). 
 
The plant roots of E. longifolia are widely used in traditional medicine for 
healing of boils, after birth, for fever, syphilis, wound ulcer and bleeding gums 
(Burkill, 1966). E. longifolia roots have many chemical constituents. Several of the 
chemical constituents have been isolated from the roots and characterized, consisting 
of alkaloids (Mitsunaga et al., 1994; Kanchanapoom, 2001), squalene derivatives 
(Morita et al., 1993; Itokawa et al., 1991a; 1991b), quassinoids (Chan et al., 1989; 
1991; 1992; Ang et al., 2002), tirucallane-type triterpenes (Itokawa et al., 1992) and 
biphenylneolignan (Morita et al., 1992). Low et al. (2011) determined the major 
quassinoids in the standardized extract of E. longifolia. The extract contained 4.0%, 
18.5%, 0.7% and 9.5% of 13α(21)-epoxyeurycomanone, eurycomanone, 13α,21-
dihydroeurycomanone and eurycomanol, respectively (Figure 1.2).  
 
Many studies on E. longifolia showed that the constituents in E. longifolia 
possess antiplasmodial activity (Chan et al., 2004; 2005), cytotoxic effect (Kardono 
et al., 1991), plant growth inhibitors, anti-schistosomal, anti-tumor promoting agent 
and anti-parasitic activity (Jiwajinda et al., 2001; 2002), apoptosis effects in HepG2 
cells (Zakaria et al., 2009), antipyretic activity (Chan et al.,1995) and aphrodisiac 
property (Ang & Sim 1997; Ang & Ngai, 2001; Ang & Lee, 2002; Ang et al., 2003b). 
Hitherto, only a few studies have been published on herb-drug interaction. One study 
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by Salman et al (2010) on the effect of E. longifolia water-based extract on the 
bioavailability of propranolol showed that the extract decreased AUC (29%), reduced 
Cmax (42%) and prolonged Tmax (86%) of propranolol. 
 
 
13α(21)-epoxyeurycomanone (1) 
 
Eurycomanone (2) 
 
13α,21-dihydroeurycomanone (3) 
 
Eurycomanol (4) 
 
Figure 1.2 Chemical structures of 13α(21)-epoxyeurycomanone (1), 
eurycomanone (2), 13α,21-dihydroeurycomanone (3) and eurycomanol (4) in the 
standardized  extract of E. longifolia (Chan et al., 2009; Low et al., 2011) 
 
 
 
 Tongkat Ali is claimed as a testosterone booster (Taufiqurrachman & 
Wibowo, 2000; Low et al., 2013), has been widely used in society and contains 
many constituents. It does not affect in the same way as other aphrodisiacs, which 
show their effects immediately.  It should be used regularly over time. Patient may 
use concurrently with another medicine, so a herb-drug interaction may occur and 
therefore affect the drug therapeutic effect or even generate toxicity. Therefore, study 
about the effects of the standardized extract of E. longifolia on the pharmacological 
profile involving drug metabolism phase I and II, and pharmacokinetics effect when 
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used concurrently with a modern drug, for example rosiglitazone, needs to be 
conducted to further examine efficacy and safety of the herbal remedies.   
 
1.2.4 Rosiglitazone 
Rosiglitazone is used as a model drug in this study because of the metabolic 
pathways through the N-demethylation. Rosiglitazone is a potent antidiabetic agent 
(Young et al., 1998; Patel et al., 1998) and is usually combined with metformin to 
treat the type 2 diabetes patients (Matthews et al., 1999).  Rosiglitazone decreases 
the insulin resistance by interacting with the peroxisome proliferator activated 
receptor-γ (PPAR-γ). The activation of PPAR-γ will increase insulin sensitivity in 
the liver, adipose tissue and skeletal muscles, which lead to changes of gene 
expression that involves metabolism of glucose (Lehmann et al., 1995; Matthews et 
al., 1999). PPAR-γ is an important factor that influences various genes involved in 
the induction of adipocyte-specific gene expression, lipid metabolism and glucose 
homeostasis. One study has shown that changes in lipid metabolism may mediate the 
therapeutic effects of rosiglitazone (PPAR-γ agonist) (Shockley et al., 2009; 
Muurling et al., 2003; Jucker et al., 2003). PPAR-γ activation will inhibit the nitric 
oxide (NO) overproduction, tumor necrosis factor (TNF)-α and interleukin (IL)-6 
expression, suppresses COX-2 and induction of inducible NO-synthase (iNOS) by 
repression of NF-κB and activation of the activator protein-1 (Inoue et al., 2000; 
Maggi et al., 2000). NO gas release is one factor that can alter erection process 
through the activation of guanylate cyclase (GC) enzyme that converts the nucleotide 
guanosine tri-phosphate (GTP) into cyclic guanosine monophosphate (cGMP) 
(Palmer, 1999). 
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Rosiglitazone is used in the treatment of diabetes and is usually administered 
at doses 4 to 8 mg/day (Sahi et al., 2003). The absorption of rosiglitazone is rapid 
and essentially complete, with absolute bioavailability estimated to be 99 % after oral 
tablet dosing and 95 % after oral solution dosing, and clearance was primarily in 
metabolic form. In human, the major routes of metabolism are N-demethylation and 
hydroxylation with subsequent conjugation. Figure 1.3 shows the metabolic 
pathways of rosiglitazone in vitro. Glucuronide conjugation is found lower (7.5 % of 
administered) than sulphate conjugation (37.8 %) (Baldwin et al., 1999; Cox et al., 
2000). It was reported that rosiglitazone was a strong inhibitors of CYP2C8 and 
CYP3A4, in vitro, and CYP2D6 was slightly inhibited by rosiglitazone (Sahi et al., 
2003). CYP2C8 was primarily responsible for the hydroxylation and N-
demethylation of rosiglitazone in human liver microsomes; with minor contributions 
from CYP2C9 (Baldwin et al., 1999). 
  
Figure 1.3   Metabolic pathways of rosiglitazone in vitro with the major routes of 
metabolism are N-demethylation and hydroxylation (Baldwin et al., 1999) 
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1.2.5 Aminopyrine 
Aminopyrine is an analgesic and antipyretic drug, is rapidly and almost 
completely absorbed after oral administration. The time to reach the maximum 
plasma concentration is about 1.5 h and the time of half-life is 2 to 3 h. The major 
route of aminopyrine metabolism is through demethylation and acylation pathways, 
with unchanged aminopyrine excreted in small quantities (10%). Aminopyrine is 
mainly N-demethylated by CYP3A and CYP2B in rats (Kamataki, 1993; Timbrell, 
2001) and CYP2C in humans (Woolf, 1999). Some studies of drug-drug interaction 
by using aminopyrine as substrate have been performed (Gemayel et al, 2001; Di 
Nucci et al, 1979; Vessel et al, 1976). Herb-drug interaction study of aminopyrine 
with some herbal medicines has been reported. Abas et al. (1998) reported about the 
interaction of aminopyrine with seven traditional medicines in rat hepatocytes. The 
results showed that some of these preparations affected significantly aminopyrine 
metabolism. Han & Hussin (2007) had studied about the effect of O. stamineus 
Benth on aminopyrine metabolism. O. stamineus showed significant increase in the 
aminopyrine N-demethylase activity. Interaction study of O. stamineus and M. 
citrifolia with aminopyrine metabolism in rats have been reported by Chin et al. 
(2009). Recently, it was reported that in vivo administration of Faizol Ubat Batuk 
(FUB) in rat affected phase I aminopyrine metabolism. The effects of FUB were 
related with disease and gender (Taher & Hussin, 2011). On the other hand, 
Ravindranath & Varada (1989) studied about aminopyrine N-demethylase activity in 
mouse liver and brain that was associated with cytochrome P-450 acitity and sex-
difference. Activity of aminopyrine N-demethylase in human liver microsomes from 
31 different patients has been reported. The results suggested that in the population 
studied, inter-individual differences may be due to the occurrence of different 
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amounts of the same enzyme, rather than the presence of different enzymes (Garcia-
Agundez et al., 1990). 
In phase I metabolism, many reactions such as hydroxylation, reduction or 
dealkylation can occur. Dealkylation reaction occurs with drugs or xenobiotics that 
have the functional groups such as an alkoxy group or an alkyl substituted thiol, a 
secondary and tertiary amine and will produce the formaldehyde (HCHO) (Gibson & 
Skett, 2001). Depending on the type of atom that binds the alkyl group, these 
reactions are divided to the N-, O- or S-dealkylations (Timbrell, 2001, Gibson & 
Skett, 2001). Aminopyrine and rosiglitazone are examples of drugs that are 
metabolized through N-demethylation. The reaction occurs in two stages, the first is 
attachment of the hydroxyl group to the methyl group next to the nitrogen and then 
the decomposition process of this intermediate with the loss of formaldehyde. The 
formaldehyde formation can be determined by Hantzsch reaction (Figure 1.4) 
 
  
 
 
 
A 
 
 
         Unstable intermediate              Formaldehyde 
 
 
 
 
B 
 
     Acetylacetone                       Formaldehyde                             3,5-Diacetyl-1-4 
                                                                                               Dihydrolutidine (λmax 415 nm) 
 
Figure 1.4 The mechanism of N-demethylation reaction (A) and colorimetric 
determination of formaldehyde by Hantzsch reaction (B) (Gibson 
& Skett, 1994) 
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1.2.6 Theoretical framework 
The belief in society that natural products are safer than synthetic drugs has 
led to the dramatic growth of herbal medicine usage. Like synthetic drugs, herbal 
remedies may also cause herb-drug interactions or adverse effects. Knowledge of the 
effect of herbal medicines on the pharmacological profile and pharmacokinetics of 
drugs are needed to explain and predict the various events related to the efficacy and 
toxicity of herbal preparations. However, study about the herb-drug interactions of 
herbal preparations have not been systematically studied, especially for Eurycoma 
longifolia that is widely used in Indonesia, Malaysia and Vietnam.  
 
Tongkat Ali (E. longifolia) is claimed as an aphrodisiac. The effect will be 
felt gradually after a certain period of usage in about one week or more. It is possible 
that type 2 or type 1 diabetic patients that had experience on erectile dysfunction uses 
concurrently Tongkat Ali with an antidiabetic agent (such as rosiglitazone). An 
antidiabetic agent is usually used for a long period of time. While rosiglitazone is a 
ligand for PPAR-γ, PPAR-γ is a critical transcription factor that influences numerous 
genes related to lipid metabolism and glucose homeostasis. This suggests that 
changes in lipid metabolism may mediate the therapeutic effects of PPAR-γ agonist. 
This is due to the fact that PPAR-γ activation will inhibit NO overproduction, and 
NO gas release is one factor that can alter erection process through the activation of 
GC enzyme that converts GTP into cGMP. Herb-drug interaction may occur if 
Tongkat Ali and rosiglitazone are used concurrently for a long time. 
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1.2.7 Objectives of study 
There are five objectives in this study: 
a. To examine the in vitro and in vivo effects of the standardized extract of E. 
longifolia on phase I hepatic drug metabolizing enzymes on Sprague-Dawley 
rats. 
b. To evaluate the effect of the standardized extract of E. longifolia on the 
mechanism of drug metabolism in rat liver. 
c. To examine the in vitro and in vivo effects of the standardized extract of E. 
longifolia on phase II hepatic drug metabolizing enzymes on Sprague-Dawley 
rats. 
d. To examine the effect of the standardized extract of E. longifolia on the 
human cytochrome P450 (CYP450) activity. 
e. To examine the effect of the standardized extract of E. longifolia on the 
pharmacokinetic profile and bioavailability of rosiglitazone when co-
administered orally. 
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CHAPTER TWO 
MATERIALS AND METHODS 
 
 
2.1   MATERIALS 
2.1.1  Sources of chemicals used 
 
 
Table 2.1 Chemicals for standardization of Eurycoma longifolia extract  
(TAF-273) by using LC-MS 
 
No Name of chemicals Company, Country 
1 ACN (acetonitrile) (HPLC grade) Merck, Germany 
2 Formic acid of HPLC grade Sigma Chemicals Co, USA 
3 Methanol of HPLC grade Merck, Germany 
4 Eurycomanone standard (purity ≥95%) Kind gift from Prof. Chan 
Kit Lam 
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Table 2.2 Chemicals for phase I metabolism studies and mechanism study 
No Name of chemicals 
 
Company, Country 
1 Aminopyrine  (4-Dimethyl-amino-antipyrine) Sigma Chemicals Co, USA 
2 Barium hydroxide R & M Chemicals, UK 
3 Calcium chloride Riedel-deHaen, France 
4 Dimethyl  sulfoxid (Methyl sulfoxide) Fluka, Switzerland 
5 Diethyl ether BDH Laboratory Supplies, UK 
6 Disodium hydrogen phosphate  R & M Chemicals, UK 
7 Formaldehyde solution 37% Merck, Germany 
8 Furafylline Sigma Chemicals Co, USA 
9 Genistein Calbiochem, Germany 
10 Glucose monohydrate Riedel-deHaen, France 
11 Gpp [guanylyl-5’-imidodiphosphate tetralithium 
salt] 
Calbiochem, Germany 
12 IBMX [3-isobutyl-1-methylxanthine] Calbiochem, Germany 
13 KT5823 [9-methoxy-9-methoxycarbonyl-8-
methyl-2,3,9,10-tetrahydro-8,11-epxoy-
1H,8H,11H-2,7b-11a-
triazadibenzo(a,g)cycloocta(cde)-trinden-1-one] 
Calbiochem, Germany 
14 KT5720 [9S,10S,12R)-2,3,9,10,11,12-
Hexahydro-10-hydroxy-9-methyl-1-oxo-9,12-
epoxy-1H-diindolo[1,2,3-fg:3′,2′,1′-
kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-
carboxylic acid hexyl ester] 
Calbiochem, Germany 
15 L-ornithine [L-N5-(1-iminoethyl)-ornithine] Calbiochem, Germany 
16 Magnesium chloride BDH Laboratory Supplies, UK 
17 Magnesium sulphate BDH Laboratory Supplies, UK 
18 OKA [okadaic acid potassium salt] Calbiochem, Germany 
19 PMA [phorbol-12-myristate-13-acetate] Calbiochem, Germany 
20 Potassium chloride   R & M Chemicals, UK 
21 Potassium dihydrogen orthophosphate  Ajax Chemicals, Australia 
22 Rosiglitazone maleate Wuhan Sunrise Technology, 
China 
23 Sodium hydrogen bicarbonate R & M Chemicals, UK 
24 Sodium chloride BDH Laboratory Supplies, UK 
25 Streptozotocin Sigma Chemicals Co, USA 
26 TPA [trifluoperazine dihydrochloride] Sigma Chemicals Co, USA 
27 Trypan blue Sigma Chemicals Co, USA 
28 Zinc sulphate heptahydrate  R & M Chemicals, UK 
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Table 2.3 Chemicals for phase II metabolism studies (UGT and GST assay) 
No Name of chemicals Company, Country 
1 BioRad protein assay kit Hercules, CA, USA 
2 CDNB [1-chloro-2,4-dinitrobenzene]  Sigma Chemicals Co, USA 
3 Diethyl ether  BDH Laboratory Supplies, UK 
4 Disodium hydrogen phosphate  R & M Chemicals, UK 
5 Glutathione, reduced form  Sigma Chemicals Co, USA 
6 Glycerol  Sigma Chemicals Co, USA 
7 Magnessium chloride  ChemAR, Systerm, Malaysia 
8 p-Nitrophenol  Sigma Chemicals Co, USA 
9 Potassium chloride  R & M Chemicals, UK 
10 Potassium dihydrogen orthophosphate  Ajax Chemicals, Australia 
11 Sodium diclofenac  Sigma Chemicals Co, USA 
12 Sodium hydroxide  J&J Laboratory Chemicals, Austria 
13 Tannic acid HmbG Chemicals, Malaysia 
14 Trichloroacetic acid  Fisher Scientific, USA 
15 Tris-HCl  Sigma Chemicals Co, USA 
16 UDPGA [Uridine 5’-diphosphoglucoronic 
acid  
Sigma Chemicals Co, USA 
17 Triton X-100 ICN Biomedicals, Inc, USA 
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Table 2.4 Chemicals for human cytochrome P-450 study 
No Name of chemicals Company, Country 
1 a. P450-GLO
TM
 CYP1A2 Assay kit,  includes: 
    - Luciferin-ME (luciferin 6’methyl ether), 5 mM 
    - Luciferin detection reagent (lyophilized) 
    - Reconstitution buffer 
b. Human CYP1A2 Enzyme System kit, includes: 
    - CYP1A2 (1pmol/µL) + reductase 
    - Control membranes 
    - 1M Potassium phosphate buffer (pH 7.4) 
    - Luciferin-free water 
    - Solution A, NADPH regeneration system 
    - Solution B, NADPH regeneration system 
 
Promega, USA 
2 a. P450-GLO
TM
 CYP2C9 Assay kit,  includes: 
    - Luciferin-H (6’ deoxyluciferin), 5 mM 
    - Luciferin detection reagent (lyophilized) 
    - Reconstitution buffer 
b. Human CYP2C9 Enzyme System kit, includes: 
    - CYP2C9 (1pmol/µL) + reductase + b5 
    - Control membranes 
    - 1M Potassium phosphate buffer (pH 7.4) 
    - Luciferin-free water 
    - Solution A, NADPH regeneration system 
    - Solution B, NADPH regeneration system 
 
Promega, USA 
3 a. P450-GLO
TM
 CYP2C19 Assay kit,  includes: 
    - Luciferin-H EGE (ethylene glycol ester of  
      6’ deoxyluciferin), 123 µg/bottle 
    - Luciferin detection reagent (lyophilized) 
    - Reconstitution buffer with esterase 
b. Human CYP2C19 Enzyme System kit, includes: 
    - CYP2C19 (1pmol/µL) + reductase + b5 
    - Control membranes 
    - 1M Potassium phosphate buffer (pH 7.4) 
    - Luciferin-free water 
    - Solution A, NADPH regeneration system 
    - Solution B, NADPH regeneration system 
 
Promega, USA 
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Table 2.4 Continued 
No Name of chemicals Company, Country 
4 a. P450-GLO
TM
 CYP2D6 Assay kit,  includes: 
    - Luciferin-ME EGE(ethylene glycol ester of  
       luciferin 6’ ethyl ether), 900 µg/bottle 
    - Luciferin detection reagent (lyophilized) 
    - Reconstitution buffer with esterase 
b. Human CYP2D6 Enzyme System kit, includes: 
    - CYP2D6 (1pmol/µL) + reductase  
    - Control membranes 
    - 1M Potassium phosphate buffer (pH 7.4) 
    - Luciferin-free water 
    - Solution A, NADPH regeneration system 
    - Solution B, NADPH regeneration system 
 
Promega, USA 
5 a. P450-GLO
TM
 CYP3A4 Assay kit,  includes: 
    - Luciferin-BE (luciferin 6’ benzyl ether), 5 mM 
    - Luciferin detection reagent (lyophilized) 
    - Reconstitution buffer 
b. Human CYP3A4 Enzyme System kit, includes: 
    - CYP3A4 (1pmol/µL) + reductase + b5 
    - Control membranes 
    - 1M Potassium phosphate buffer (pH 7.4) 
    - Luciferin-free water 
    - Solution A, NADPH regeneration system 
    - Solution B, NADPH regeneration system 
 
Promega, USA 
6 Beetle luciferin [(4S)-4-5-dihydro-2-(6-
hydroxybenzothiazolyl)-4-thiazolecarboxylic acid or 
D-luciferin] potassium salt 
 
Promega, USA 
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Table 2.5 Chemicals for pharmacokinetic study 
No Name of chemicals Company, Country 
1 Acetonitrile (ACN) (HPLC grade) Merck, Germany 
2 Ethyl acetate (HPLC grade) Merck, Germany 
3 Methanol (HPLC grade) Merck, Germany 
4 Disodium hydrogen phosphate  R & M Chemicals, UK 
5 Hydrochloric acid (HCL, analytical grade) Fisher Scientific, UK 
6 Potassium dihydrogen orthophosphate  Ajax Chemicals, Australia 
7 Rosiglitazone maleate Wuhan Sunrise Technology, 
China 
8 
9 
Triethylamine (analytical grade) 
Polyethylene glycol-400 (PEG 400) 
Acros Organics, USA 
Sigma Chemicals Co, USA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
